Covered recipient · General Payments record
PAIGE C WALEND
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2019–2025
$3,529.57
- Reported across 157 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $286.03 | 16 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $70.23 | 4 |
| DEXCOM, INC. | $59.30 | 3 |
| Novo Nordisk AS | $46.01 | 3 |
| GlaxoSmithKline, LLC. | $37.88 | 2 |
| ITI, Inc. | $32.94 | 2 |
| Lilly USA, LLC | $21.88 | 1 |
| ABBVIE INC. | $17.79 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.79 | 09/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1204672383 | CMS |
| Dexcom, Inc. | $20.05 | 05/28/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1250513277 | CMS |
| Dexcom, Inc. | $18.28 | 09/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1250513279 | CMS |
| Dexcom, Inc. | $20.97 | 11/24/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1250513281 | CMS |
| GlaxoSmithKline, LLC. | $14.65 | 04/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1190348564 | CMS |
| GlaxoSmithKline, LLC. | $23.23 | 06/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1190725312 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.04 | 06/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1241419114 | CMS |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $18.90 | 11/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1241419116 | CMS |
| Lilly USA, LLC | $21.88 | 05/12/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186773078 | CMS |
| Novo Nordisk Inc | $15.43 | 07/07/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188139132 | CMS |
| Novo Nordisk Inc | $14.14 | 08/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188512375 | CMS |
| Novo Nordisk Inc | $16.44 | 09/08/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1188156065 | CMS |
| PFIZER INC. | $16.65 | 02/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1231545743 | CMS |
| PFIZER INC. | $18.02 | 06/03/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1228904134 | CMS |
| PFIZER INC. | $19.44 | 08/11/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1229262035 | CMS |
| PFIZER INC. | $16.12 | 12/04/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1229405785 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.